IN Esketamine and IV Ketamine: Results of a multi-site observational study assessing the effectiveness and tolerability of two novel therapies for treatment-resistant depression.

Autor: Gutierrez G; Department of Psychiatry, Queen's University, and Providence Care, Kingston, Ontario, Canada., Swainson J; Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada., Ravindran N; Department of Psychiatry, University of Toronto, Toronto, ON. Centre for Addiction and Mental Health, Toronto, ON, Canada., Lam RW; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada., Giacobbe P; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Karthikeyan G; Alberta Hospital Edmonton / Medical Director of Envision Mind Care, Edmonton, Alberta, Canada., Kowara A; Department of Psychiatry, University of Toronto, Toronto, ON. Centre for Addiction and Mental Health, Toronto, ON, Canada., Do A; Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; Department of Psychiatry, Université de Montréal, Montreal, QC, Canada., Baskaran A; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Nestor SM; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. Sunnybrook Health Sciences Centre, Toronto, ON, Canada., Kang MJY; Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada; Imaging Genetics Centre, Mark and Mary Stevens Neuroimaging & Informatics Institute, Keck School of Medicine, University of Southern California, USA., Biorac A; Department of Psychiatry, Queen's University, and Providence Care, Kingston, Ontario, Canada; Centre for Neuroscience Studies, Queen's University, Kingston, Ontario, Canada., Vazquez G; Department of Psychiatry, Queen's University, and Providence Care, Kingston, Ontario, Canada; Providence Care Hospital, Kingston, Ontario, Canada. Electronic address: g.vazquez@queensu.ca.
Jazyk: angličtina
Zdroj: Psychiatry research [Psychiatry Res] 2024 Oct; Vol. 340, pp. 116125. Date of Electronic Publication: 2024 Aug 05.
DOI: 10.1016/j.psychres.2024.116125
Abstrakt: Intravenous (IV) ketamine and intranasal (IN) esketamine are novel therapies to manage treatment resistant depression within major depressive disorder (MDD-TRD). This is a multi-site observational study aiming to assess the real-world effectiveness and tolerability of these novel therapies in the management of MDD-TRD. 53 patients were referred to receive IV ketamine (n = 26, 69.23 % female, 52.81 ± 14.33 years old) or IN esketamine (n = 27, 51.85 % female, 43.93 ± 13.57 years old). Treatment effectiveness was assessed using the Montgomery and Åsberg Depression Rating Scale (MADRS) for depression severity and item 10 of the MADRS for suicidal ideation (SI). Tolerability was assessed by systematically tracking side effects and depersonalization using the 6-item Clinician administered dissociative symptom scale (CADSS-6). The data was analyzed using descriptive statistics, risk ratio and effect size. Both IV ketamine and IN esketamine significantly reduced depressive symptoms and suicidal ideation by treatment endpoint. Patients receiving IN esketamine, and patients receiving IV ketamine had a similar risk of developing side effects. All side effects reported were mild and transient. These results suggested that both IV ketamine and IN esketamine are effective in the management of depressive symptoms and were well tolerated. Therefore, the results of this study could serve to inform clinical practice.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jennifer Swainson reports a relationship with AbbVie Inc that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Bausch Health Companies Inc US that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Biron Health Group that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Eisai Inc that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Idorsia Pharmaceuticals Ltd that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Lundbeck LLC that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: consulting or advisory and speaking and lecture fees. Jennifer Swainson reports a relationship with Canadian Psychiatric Association that includes: consulting or advisory and speaking and lecture fees. Raymond W. Lam reports a relationship with AbbVie Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Asia-Pacific Economic Cooperation that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Bausch Health Companies Inc US that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with BC leading edge foundation that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Brain Canada Foundation that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Canadian Institutes of Health Research that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Canadian Network for Mood and Anxiety Treatments that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Carnot Pharma LLC that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with CB solutions that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Genome British Columbia that includes: consulting or advisory, paid expert testimony, and speaking and lecture fees. Raymond W. Lam reports a relationship with Grand Challenges Canada that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Healthy Minds Canada that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Janssen Pharmaceuticals Inc that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Lundbeck LLC that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Michael Smith Foundation for Health Research that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Mitacs that includes: consulting or advisory, funding grants, and travel reimbursement. Raymond W. Lam reports a relationship with Neurotorium that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Ontario Brain Institute that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Shanghai Mental Health Center that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Unity Health that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with Vancouver Coastal Health Research Institute that includes: consulting or advisory, funding grants, and speaking and lecture fees. Raymond W. Lam reports a relationship with VGH and UBC Hospital Foundation that includes: consulting or advisory, funding grants, and speaking and lecture fees. Andre Do reports a relationship with Janssen Pharmaceuticals Inc that includes:. Andre Do reports a relationship with AbbVie Inc that includes: consulting or advisory and funding grants. Andre Do reports a relationship with Canadian Institutes of Health Research that includes: consulting or advisory and funding grants. Andre Do reports a relationship with Otsuka Pharmaceutical Co Ltd that includes: consulting or advisory and funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: